β2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women

K. Katano, K. Aoki, H. Sasa, M. Ogasawara, Eiji Matsuura, Y. Yagami

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Our aim was to elucidate prospectively whether β2-glycoprotein I-dependent anticardiolipin antibodies (β2GPI-dependent aCL; autoimmune type) can predict an adverse pregnancy outcome in healthy pregnant women and whether β2GPI-dependent aCL should be applied for routine screening of the pregnant population. A prospective cohort study was performed on 1600 healthy pregnant women from whom blood samples were obtained at about week 10 of gestation. We used a modified enzyme-linked immunosorbent assay with which to divide the subjects into three study groups: β2GPI-dependent aCL positive, β2GPI-independent aCL positive and aCL negative. Their subsequent pregnancy outcomes were ascertained and the three study groups were compared statistically for the following poor pregnancy outcomes: intrauterine fetal death (IUFD) after 12 gestational weeks, intrauterine growth retardation (IUGR) and pre-eclampsia. The total number of patients eligible for this study was 1125. The prevalence of β2GPI-dependent aCL positive was eight (0.7%), β2GPI-independent aCL positive was 17 (1.5%) and aCL negative was 1100 (97.8%). β2GPI-dependent aCL positivity was significantly associated with poor pregnancy outcome: 25.0% of β2GPI-dependent aCL-positive and 0.5% of a(l l-negative patients experienced IUFD [relative risk 52.4; 95% confidence interval (CI), 12.7 - 216.3; P = 0.0009]; 37.5% of β2GPI-dependent aCL-positive and 2.9% of aCL-negative patients experienced IUGR (relative risk 18.4; 95% CI, 4.6-74.0; P = 0.001); and 50.0% of β2GPI-dependent aCL-positive and 4.0% aCL-negative patients experienced pre-eclampsia (relative risk 22.1; 95% CI, 5.7-85.7; P = 0.0002). In contrast, β2GPI-independent aCL did not show any significant association with such adverse pregnancy outcomes. β2GPI-dependent aCL are significantly highly associated with adverse pregnancy outcomes in healthy pregnant women and can be used for prediction purposes, whereas β2GPI-independent aCL cannot. Our results suggest that routine screening for β2GPI-dependent aCL should be introduced for the general pregnant population.

Original languageEnglish
Pages (from-to)509-512
Number of pages4
JournalHuman Reproduction
Volume11
Issue number3
Publication statusPublished - Mar 1996
Externally publishedYes

Fingerprint

Anticardiolipin Antibodies
Pregnancy Outcome
Pregnant Women
Glycoproteins
Fetal Death
Fetal Growth Retardation
Confidence Intervals
Pre-Eclampsia
Population
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Prospective Studies
Pregnancy

Keywords

  • β2-glycoprotein I
  • Anticardiolipin antibodies
  • Pregnancy outcome

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

β2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. / Katano, K.; Aoki, K.; Sasa, H.; Ogasawara, M.; Matsuura, Eiji; Yagami, Y.

In: Human Reproduction, Vol. 11, No. 3, 03.1996, p. 509-512.

Research output: Contribution to journalArticle

@article{7bc67f3d05f2402ab131c4175ffcbf90,
title = "β2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women",
abstract = "Our aim was to elucidate prospectively whether β2-glycoprotein I-dependent anticardiolipin antibodies (β2GPI-dependent aCL; autoimmune type) can predict an adverse pregnancy outcome in healthy pregnant women and whether β2GPI-dependent aCL should be applied for routine screening of the pregnant population. A prospective cohort study was performed on 1600 healthy pregnant women from whom blood samples were obtained at about week 10 of gestation. We used a modified enzyme-linked immunosorbent assay with which to divide the subjects into three study groups: β2GPI-dependent aCL positive, β2GPI-independent aCL positive and aCL negative. Their subsequent pregnancy outcomes were ascertained and the three study groups were compared statistically for the following poor pregnancy outcomes: intrauterine fetal death (IUFD) after 12 gestational weeks, intrauterine growth retardation (IUGR) and pre-eclampsia. The total number of patients eligible for this study was 1125. The prevalence of β2GPI-dependent aCL positive was eight (0.7{\%}), β2GPI-independent aCL positive was 17 (1.5{\%}) and aCL negative was 1100 (97.8{\%}). β2GPI-dependent aCL positivity was significantly associated with poor pregnancy outcome: 25.0{\%} of β2GPI-dependent aCL-positive and 0.5{\%} of a(l l-negative patients experienced IUFD [relative risk 52.4; 95{\%} confidence interval (CI), 12.7 - 216.3; P = 0.0009]; 37.5{\%} of β2GPI-dependent aCL-positive and 2.9{\%} of aCL-negative patients experienced IUGR (relative risk 18.4; 95{\%} CI, 4.6-74.0; P = 0.001); and 50.0{\%} of β2GPI-dependent aCL-positive and 4.0{\%} aCL-negative patients experienced pre-eclampsia (relative risk 22.1; 95{\%} CI, 5.7-85.7; P = 0.0002). In contrast, β2GPI-independent aCL did not show any significant association with such adverse pregnancy outcomes. β2GPI-dependent aCL are significantly highly associated with adverse pregnancy outcomes in healthy pregnant women and can be used for prediction purposes, whereas β2GPI-independent aCL cannot. Our results suggest that routine screening for β2GPI-dependent aCL should be introduced for the general pregnant population.",
keywords = "β2-glycoprotein I, Anticardiolipin antibodies, Pregnancy outcome",
author = "K. Katano and K. Aoki and H. Sasa and M. Ogasawara and Eiji Matsuura and Y. Yagami",
year = "1996",
month = "3",
language = "English",
volume = "11",
pages = "509--512",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - β2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women

AU - Katano, K.

AU - Aoki, K.

AU - Sasa, H.

AU - Ogasawara, M.

AU - Matsuura, Eiji

AU - Yagami, Y.

PY - 1996/3

Y1 - 1996/3

N2 - Our aim was to elucidate prospectively whether β2-glycoprotein I-dependent anticardiolipin antibodies (β2GPI-dependent aCL; autoimmune type) can predict an adverse pregnancy outcome in healthy pregnant women and whether β2GPI-dependent aCL should be applied for routine screening of the pregnant population. A prospective cohort study was performed on 1600 healthy pregnant women from whom blood samples were obtained at about week 10 of gestation. We used a modified enzyme-linked immunosorbent assay with which to divide the subjects into three study groups: β2GPI-dependent aCL positive, β2GPI-independent aCL positive and aCL negative. Their subsequent pregnancy outcomes were ascertained and the three study groups were compared statistically for the following poor pregnancy outcomes: intrauterine fetal death (IUFD) after 12 gestational weeks, intrauterine growth retardation (IUGR) and pre-eclampsia. The total number of patients eligible for this study was 1125. The prevalence of β2GPI-dependent aCL positive was eight (0.7%), β2GPI-independent aCL positive was 17 (1.5%) and aCL negative was 1100 (97.8%). β2GPI-dependent aCL positivity was significantly associated with poor pregnancy outcome: 25.0% of β2GPI-dependent aCL-positive and 0.5% of a(l l-negative patients experienced IUFD [relative risk 52.4; 95% confidence interval (CI), 12.7 - 216.3; P = 0.0009]; 37.5% of β2GPI-dependent aCL-positive and 2.9% of aCL-negative patients experienced IUGR (relative risk 18.4; 95% CI, 4.6-74.0; P = 0.001); and 50.0% of β2GPI-dependent aCL-positive and 4.0% aCL-negative patients experienced pre-eclampsia (relative risk 22.1; 95% CI, 5.7-85.7; P = 0.0002). In contrast, β2GPI-independent aCL did not show any significant association with such adverse pregnancy outcomes. β2GPI-dependent aCL are significantly highly associated with adverse pregnancy outcomes in healthy pregnant women and can be used for prediction purposes, whereas β2GPI-independent aCL cannot. Our results suggest that routine screening for β2GPI-dependent aCL should be introduced for the general pregnant population.

AB - Our aim was to elucidate prospectively whether β2-glycoprotein I-dependent anticardiolipin antibodies (β2GPI-dependent aCL; autoimmune type) can predict an adverse pregnancy outcome in healthy pregnant women and whether β2GPI-dependent aCL should be applied for routine screening of the pregnant population. A prospective cohort study was performed on 1600 healthy pregnant women from whom blood samples were obtained at about week 10 of gestation. We used a modified enzyme-linked immunosorbent assay with which to divide the subjects into three study groups: β2GPI-dependent aCL positive, β2GPI-independent aCL positive and aCL negative. Their subsequent pregnancy outcomes were ascertained and the three study groups were compared statistically for the following poor pregnancy outcomes: intrauterine fetal death (IUFD) after 12 gestational weeks, intrauterine growth retardation (IUGR) and pre-eclampsia. The total number of patients eligible for this study was 1125. The prevalence of β2GPI-dependent aCL positive was eight (0.7%), β2GPI-independent aCL positive was 17 (1.5%) and aCL negative was 1100 (97.8%). β2GPI-dependent aCL positivity was significantly associated with poor pregnancy outcome: 25.0% of β2GPI-dependent aCL-positive and 0.5% of a(l l-negative patients experienced IUFD [relative risk 52.4; 95% confidence interval (CI), 12.7 - 216.3; P = 0.0009]; 37.5% of β2GPI-dependent aCL-positive and 2.9% of aCL-negative patients experienced IUGR (relative risk 18.4; 95% CI, 4.6-74.0; P = 0.001); and 50.0% of β2GPI-dependent aCL-positive and 4.0% aCL-negative patients experienced pre-eclampsia (relative risk 22.1; 95% CI, 5.7-85.7; P = 0.0002). In contrast, β2GPI-independent aCL did not show any significant association with such adverse pregnancy outcomes. β2GPI-dependent aCL are significantly highly associated with adverse pregnancy outcomes in healthy pregnant women and can be used for prediction purposes, whereas β2GPI-independent aCL cannot. Our results suggest that routine screening for β2GPI-dependent aCL should be introduced for the general pregnant population.

KW - β2-glycoprotein I

KW - Anticardiolipin antibodies

KW - Pregnancy outcome

UR - http://www.scopus.com/inward/record.url?scp=0029866061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029866061&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 509

EP - 512

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 3

ER -